AU2016208315A1 — Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Assigned to Siga Technologies Inc · Expires 2016-08-11 · 10y expired
What this patent protects
Abstract A process for producing the compound 4-trifluoromethyl-N (3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[fJisoindol-2(1H)-yl) benzamide comprising the steps of: a) heating a mixture of anti tricyclo[3.2.2.0]non-6-ene-endo-8,endo-9-dicarboxylic acid anhydride…
USPTO Abstract
Abstract A process for producing the compound 4-trifluoromethyl-N (3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[fJisoindol-2(1H)-yl) benzamide comprising the steps of: a) heating a mixture of anti tricyclo[3.2.2.0]non-6-ene-endo-8,endo-9-dicarboxylic acid anhydride,4 (trifluoromethyl)benzhydrazide, and ethanol at reflux to form a solution; b) cooling the solution; c) concentrating the solution to form a residue; and d) recrystallizing the residue from ethyl acetate and hexanes to obtain said compound. 20/12/12,ck2048 labstract,2
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.